共 50 条
- [44] Vitiligo as durvalumab's immune-related adverse event in lung cancer MEDICINA CLINICA, 2022, 158 (07): : 341 - 342
- [49] Association between immune-related adverse event timing and treatment outcomes ONCOIMMUNOLOGY, 2022, 11 (01):
- [50] Bilateral progressive orbital myositis as immune-related adverse event of pembrolizumab CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2024, 59 (04): : e388 - e388